Biotech Archives - Page 749 of 795

1 minute read

AVITA Medical Shares Climb On Topline Results From Soft Tissue Reconstruction Study, Sees PMA Submission By Year-end

August 11, 5:29 PM

AVITA Medical (NASDAQ: RCEL) announced topline results from its pivotal trial evaluating the safety and effectiveness of the RECELL System combined with meshed autograft for reduction of donor skin harvesting in soft tissue reconstruction.

RCEL

1 minute read

This Penny Stock Biotech Offloads Eye Portfolio To Focus On RNA-Editing

By Vandana Singh

August 11, 2:48 PM

ProQR Therapeutics N.V. (NASDAQ:PRQR) said it would look for a partner to take the company’s ophthalmology portfolio further into clinical trials. …

LLY

1 minute read

Allena Pharma Needs To Raise Capital To Continue As A Going Concern

By Vandana Singh

August 11, 2:47 PM

Allena Pharmaceuticals Inc (NASDAQ:ALNA) says it lacks the financial resources to conduct studies for ALLN-346 for hyperuricemia and gout in the…

ALNA

1 minute read

GeoVax Labs Shares See Volume, Co. Filed Patent Application Titled ‘VIRAL CONSTRUCTS FOR USE IN ENHANCING T-CELL PRIMING DURING VACCINATION’

By Michael Horton

August 11, 2:21 PM

https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2022169895

GOVX

2 minute read

Recalled Heartburn Pill Zantac Sets Fire To Glaxo and Sanofi Shares As Billions In Market Value Goes Up In Smoke

By Vandana Singh

August 11, 11:40 AM

Sanofi SA (NASDAQ: SNY), GSK Plc (NYSE: GSK), and Haleon Plc (NYSE: HLN) have lost a combined $40 billion in mar

GSK

1 minute read

Passage Bio Commences Initial-Stage Brain Disorder Study

By Ragothaman Srinivasan

August 11, 9:57 AM

Passage Bio (NASDAQ: PASG) has dosed the first patient in the global Phase 1/2 upliFT-D clinical trial evaluating PBFT02 for the treatment of patients with frontotemporal dementia (FTD) with granulin (GRN) mutations.

PASG

1 minute read

Deciphera’s Cancer Drug Tops Pfizer’s Sutent On Safety Front In Gastrointestinal Cancer

By Vandana Singh

August 11, 9:45 AM

The Journal of Clinical Oncology has published results from Deciphera Pharmaceuticals Inc (NASDAQ:DCPH) INTRIGUE Phase 3 study of Qinlock (ripretinib) for advanced…

DCPH

1 minute read

aTyr Pharma Shares Ascend As FDA Grants Fast Track Status To Lung Disease Candidate

By Ragothaman Srinivasan

August 11, 9:32 AM

The U.S. Food and Drug Administration (FDA) has granted Fast Track designation to aTyr Pharma’s (NASDAQ: LIFE) lead therapeutic candidate, efzofitimod (ATYR1923), for the treatment of pulmonary sarcoidosis, a major form of interstitial lung disease.

LIFE

1 minute read

FDA
News

Bionano Genomics Announces First Publication Using OGM For Detection Of Repeat Expansions In CANVAS And Adult-Onset Ataxia

By Benzinga Newsdesk

August 11, 8:04 AM

ionano Genomics, Inc. (NASDAQ:BNGO) today announced the publication of the first study to evaluate the utility of optical genome mapping (OGM) in the analysis of repeat expansion disorders. Repeat expansion disorders are

BNGO

1 minute read

Menarini Group’s Elacestrant Granted Priority Review By The U.S. FDA For Patients With ER+/HER2- Advanced Or Metastatic Breast Cancer

By Benzinga Newsdesk

August 11, 6:48 AM

Elacestrant, if approved, would be the first oral selective estrogen receptor degrader (SERD) to be available for patients suffering from 2L and 3L ER+/HER2- advanced or metastatic breast

RDUS